---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-008512"
form_type: "8-K/A"
ticker: "PMCB"
cik: "0001157075"
company_name: "PharmaCyte Biotech, Inc."
filed_at: "2025-11-18T23:59:59+00:00"
generated_at: "2026-05-16T18:42:46.231694+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# PharmaCyte acquires $3M convertible stake in Q/C Technologies; Q/C has going concern

## Summary
- PharmaCyte bought Q/C Series H convertible preferred shares and warrants for $3M, convertible into 600,000 common shares each.
- Q/C's auditors express substantial doubt about its ability to continue as a going concern due to net losses and negative cash flows.
- Pro forma combined financials reflect the transaction; Q/C's financial statements show recurring operating losses.
- Warrants expire five years after stockholder approval of issuance exceeding 19.99% of Q/C outstanding shares.

## SEC filing metadata
- accession: 0001683168-25-008512
- form_type: 8-K/A
- ticker: PMCB
- cik: 0001157075
- company_name: PharmaCyte Biotech, Inc.
- filed_at: 2025-11-18T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157075/000168316825008512/0001683168-25-008512-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157075/000168316825008512/pharmacyte_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-008512
- JSON: https://secwatch.observer/filing/0001683168-25-008512.json
- Plain text: https://secwatch.observer/filing/0001683168-25-008512.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.